Clinical trial
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
NCT00160589 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00160589 |
|---|---|
| Title | LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis) |
| Official title | A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR) |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rhinitis, Allergic, Perennial |
| Intervention type | Drug |
| Interventions | Levocetirizine |
| Enrollment | 729 |
| Start date | Apr 1, 2005 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 16, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: